Skip to search.
 FTSE 100 Up0.15%

More On SHP.L



  • Warrants
  • Investment Products


News & Info


Analyst Coverage



Shire PLC (SHP.L)

5,360.00 Up 50.00(0.94%) 08:01
Add to Portfolio
ProfileGet Profile for:
Shire PLC
5 Riverwalk
Citywest Business Campus
Dublin, 24
Ireland - Map
Phone: 353 1 429 7700

Index Membership:N/A
Full Time Employees:5,016

Business Summary 

Shire plc, a biopharmaceutical company, together with its subsidiaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products. It offers various products for the treatment of attention deficit hyperactivity disorder (ADHD), including VYVANSE/ VENVANSE/ ELVANSE/ TYVENSE/ ELVANS E VUXEN/ADUVANZ; INTUNIV, an alpha-2A receptor agonist; EQUASYM, a methylphenidate hydrochloride; and ADDERALL XR, an extended release treatment for ADHD. The company also provides BUCCOLAM for epilepsy treatment; PENTASA and LIALDA/MEZAVANT for ulcerative colitis treatment; and RESOLOR, a 5-HT4 receptor agonist that is used for the treatment of chronic constipation in women. In addition, it offers REPLAGAL for the treatment of Fabry disease; ELAPRASE for the treatment of hunter syndrome; VPRIV for the treatment of type 1 Gaucher disease; and FIRAZYR and CINRYZE C1 esterase inhibitor for the treatment of hereditary angioedema. Further, the company provides FOSRENOL, a phosphate binder for use in end-stage renal disease receiving dialysis; XAGRID that is used for the reduction of elevated platelet counts in at-risk essential thrombocythemia patients; and PLENADREN for the treatment of adrenal insufficiency. Additionally, it licenses its patented antiviral products for human immunodeficiency virus and hepatitis B virus. The company also focuses on the development of resources projects in various therapeutic areas, including rare diseases, neuroscience, ophthalmics, hematology, and gastrointestinal disorders; and early development projects primarily on rare diseases. Shire plc markets its products through wholesalers and pharmacies. The company has research collaboration with ArmaGen Technologies Inc., Santaris Pharma A/S, and Sangamo. Shire plc was founded in 1986 and is based in Dublin, Ireland.

Key Statistics

Company Websites 
Home Page
Search Yahoo! UK & Ireland for:
More on Shire PLC

Key Executives 
Dr. Flemming Ornskov M.D., MBA, MPH, 57
Chief Exec. Officer, Managing Director and Director
Mr. Jeffrey Poulton , 47
Interim Chief Financial Officer
Ms. Marianne Jackson ,
Head of Global Commercial Operations
Mr. William Ciambrone ,
Head of Technical Operations
Mr. Mark J. Enyedy , 51
Head of Corp. Devel. and Interim Gen. Counsel
Amounts are as of 31 Dec 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year.
Currency in GBp.
View Insiders